Glaucoma Treatment Market Size & Share 2025 - 2034

Glaucoma Treatment Market Size

The global glaucoma treatment market size was valued at USD 6.6 billion in 2024. The market is expected to grow from USD 6.9 billion in 2025 to USD 10.5 billion in 2034 at a CAGR of 4.8%. This substantial growth is experienced due to the increasing global prevalence of glaucoma, particularly among the elderly population. The development of age-related eye diseases such as glaucoma becomes more severe with ageing. For instance, as stated by Glaucoma Research Foundation, nearly 8.4 million individuals suffered blindness due to primary open angle glaucoma in 2010, with estimates suggesting a rise to 22 million by 2040. This increase in patients is alarming, signifying the need for effective treatment.

In addition, the growing prevalence of persistent conditions such as diabetes and hypertension that are regarded as major risk factors for glaucoma, significantly advances the need for adequate and long-lasting glaucoma treatment further enhancing the market in the upcoming years. Increasing public awareness for early diagnosis and routine eye screening are improving treatment initiation rates.
 

Governments and healthcare organizations are promoting eye health, especially in high-risk populations, boosting patient engagement. The expanding adoption of new drug classes such as Rho kinase inhibitors and combination therapies is broadening the scope of glaucoma therapeutics. The surge in economic development, strongly increasing in developing countries, is resultant in enhanced access to ophthalmic care and spending on healthcare, thus fueling the growth of the market.
 

Glaucoma treatment primarily reducing the intraocular pressure (IOP) of the eye to prevent optic nerve damage and vision loss. Ophthalmology drugs, particularly glaucoma drugs include medication such as prostaglandin analogs, beta-blockers, and alpha adrenergic agonist, carbonic anhydrase inhibitors, and other drugs.
 

Glaucoma Treatment Market Trends

The increasing adoption of combination therapies due to their effectiveness and ease of use for treating glaucoma are expected to drive the market growth.
 

• The fixed-dose combinations popularity has soared owing to their ability to target multiple IOP mechanisms within a single formulation. These formulations aimed to enhance patient adherence and reduce the long-term treatment regimens intensifying its demand in coming years.
   
• This has caused the pharmaceutical companies to focus on development and innovations of combination therapies to address the patient needs. For instance, in April 2025, Santen Pharmaceutical has received approval of its marketing authorization application from the National Medical Products Administration (NMPA) of China for tafluprost/timolol maleate (Tapcom) for controlling IOP in patients suffering from open angle glaucoma or ocular hypertension. The new treatment aimed to improve the outcomes of patients suffering from glaucoma in the Indian market.
   
• Similarly, several other combination therapies include Rocklatan and Cosopt (dorzolamide/timolol), Combigan (brimonidine/timolol), and Simbrinza (brimonidine/brinzolamide) that lower IOP through combination mechanisms.
   
• Further, the initiatives on eye care awareness are approaching the market growth on early glaucoma diagnosis and treatment. Government campaigns together with non-profit organizations and healthcare coalitions are increasing the public’s knowledge regarding the need for regular screening and prompt action.
   
• The World Glaucoma Association organized the World Glaucoma Week from March 12–18, 2023, to promote awareness worldwide. This initiative aimed to focus on reducing preventable blindness through timely detection and treatment and improving access to affordable eye care services. Thus, the increasing awareness of glaucoma treatment methods further propels the market expansion.
   

Moreover, associated adverse effects of long-term treatment or incidence of optimal patient adherence, coupled with complexity of drug approval expects to hinder the market growth.
 

Trump Administration Tariffs

• The Trump administration's import tariffs of 10-25% on Canada, China and Mexico is projected to have a significant effect on the glaucoma treatment market in the U.S.
   
• The tariffs are aimed at increasing the cost of imported active pharmaceutical ingredients (APIs) and finished pharmaceutical products and medication. This increase in certain expenses will place pressure on the generic manufacturers operating in thin profits margins to increase the cost of the products.
   
• As a result, patients who are already receiving treatment for glaucoma may have limited access and face increased costs for vital medications.
   
• Furthermore, the global drug shortages crisis could be aggravated by the proposed tariffs as they would interrupt the supply chain of crucial medicines for chronic disease treatment.
   
• Thus, rising prices of drugs and equipment would initiate Medicare inflation, that would in turn impacts the patients and healthcare professionals economic.
   

Glaucoma Treatment Market Analysis

In 2021, the global market was valued at USD 6 billion. In 2023, it saw a slight increase to USD 6.4 billion, and the market further climbed to USD 6.9 billion in 2024.
 

Based on disease type, the global market is segmented into open angle glaucoma, angle closure glaucoma, and other disease types. The open angle glaucoma segment dominated the market and was valued at USD 5.4 billion in 2024, witnessing its prominence throughout the forecast period with a substantial growth of 5%.
 

• Open-angle glaucoma is the most common type of glaucoma, constituting more than 70% of cases worldwide. The condition is marked by gradual progression without treatment and slow deterioration of vision until significant eyesight impairment occurs. This change requires extensive, and in some cases, lifelong treatment, which, in turn, prompts medication arms and monitoring care.
   
• The treatment for open-angle glaucoma primarily consists of medications, which include prostaglandin analogs, beta blockers, individually marketed combinational therapies, and even proprietary combination therapies.
   
• Thus, the substantial chronic control of this state augments significant market opportunity because of the high dependence on daily treatment and regular check-ups incurred by the patients.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on the drug class, the global glaucoma treatment market is categorized into prostaglandin analogs, beta-blockers, alpha adrenergic agonist, carbonic anhydrase inhibitors, and other drug classes. The prostaglandin analogs segment held the largest market share at 33.6% in 2024 and maintained its dominant position throughout the analysis period projected to reach USD 3.7 billion by 2034.
 

• Prostaglandin analogs reduce the intraocular pressure by improving fluid drainage from the eye. They are well- tolerated for chronic diseases with little systemic side effects except for some to cause localized effects such as pigmentation of the iris and increased growth of eyelashes.
   
• These drugs are widely used for open-angle glaucoma treatment in the form of eye drops. For example, latanoprost, bimatoprost, and travoprost are available in generic forms, while tafluprost offers a preservative-free option.
   
• Moreover, the increase in glaucoma patients with aging demographic additionally increase the market for prostaglandin analogs and accelerate growth.
   

Based on the formulation, the global glaucoma treatment market is categorized into solid and liquid. In 2024, the liquid segment leads the market, generating the revenue of USD 4.4 billion and is expected to experience significant growth, with projections indicating to reach USD 7 billion by 2034.
 

• The ease of administration, effectiveness, and patient preference for liquid formulations are expected to grow the demand in the market. Eye drops are commonly prescribed as a primary therapeutic measure for glaucoma including prostaglandin analogs, beta-blockers, and other combination therapies.
   
• In addition to convenience, liquid eye medications offer refined control of the volume administered and immediate action at the site of the eye, which enhances therapeutic benefits.
   
• Continuous improvement in pharmaceutical formulation augmenting efficacy and minimizing side effects alongside increased glaucoma prevalence and heightened non-invasive treatment demand are further contributing to the segment’s growth.
   
• Therefore, the aforementioned factors have collectively strengthened the liquid formulation segment leadership in the market.
   

Based on the age group, the global glaucoma treatment market is categorized below 18, 19 – 40, 41 – 60, and above 60. The above 60 age segment holds the largest market share of 60.3% in 2024 and is projected to account for the revenue of USD 6.2 billion by 2034 at a CAGR of 4.6%.
 

• The prominence of the above 60 age group in the market was driven due to the increased risk of glaucoma with growing age.
   
• The risk of developing open-angle or angle-closure glaucoma likely increases with age due to reduction in the aqueous humor drainage, changes in the eye structure, and higher susceptibility to optic nerve damage risk. This age demographic often suffers from chronic diseases such as diabetes and hypertension that increase the risk for glaucoma that likely increases the need for treatment.
   
• Moreover, the surge in global life expectancy has increased the proportion of elderly people, expanding the patient population requiring chronic glaucoma management.
   
• Therefore, the age group above 60 remains the leading segment sustaining the revenue for glaucoma treatment.
   

Based on the distribution channel, the global glaucoma treatment market is categorized hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment currently holds the largest market share and is projected to reach USD 5.7 billion by 2034.
 

• Hospital pharmacies offer an array of prescription and OTC drugs, including advanced medications and specialized treatments, which are readily accessible for the treatment of glaucoma.
   
• These pharmacies possess an integrated healthcare infrastructure containing providers and efficiently managed supply chains, ensuring prompt provision of needed pharmaceutical services.
   
• Additionally, alongside the rising glaucoma case prevalence coupled with the increasing dependence on hospitals for effective disease management and treatment as a primary care facility has strengthened the segment’s dominance in the market.
   

In 2024, the U.S. glaucoma treatment market accounted for USD 2.24 billion revenue from USD 2.15 billion in 2023 and is anticipated to grow at a CAGR of 4.9% between the 2025 to 2034 period.
 

• The U.S. leadership is driven by the rising prevalence of glaucoma and the growing demand for innovative treatments. The aging population possesses higher susceptibility to glaucoma, prompting the need for effective management and early diagnosis solutions.
   
• For instance, a study published in JAMA Ophthalmology estimated that nearly 4.2 million adults were affected by glaucoma in 2022 out of which 1.5 million have glaucoma that impairs vision. In addition, the cases are projected to reach 6.3 million cases by 2050 according to the National Eye Institute. These predicted statistics emphasized the spurring need for treatments, alongside patients receiving timely diagnosis, which will expand the country’s growth.
   
• Additionally, the presence of major pharmaceutical companies and ongoing research further drives the development of new therapies, thereby fueling market growth.
   

Germany shows strong growth potential in the European glaucoma treatment industry.
 

• Germany strong growth was demonstrated due to its large aging population associated with high prevalence of glaucoma. Also, increased attention to eye health along with proactive glaucoma detection initiatives is increasing the need for efficient glaucoma therapy.
   
• Furthermore, the strong and well-developed pharmaceutical industry in the country, together with the continued R&D efforts for glaucoma treatments, has positioned Germany as a major player in this Europe market.
   

China glaucoma treatment market in Asia Pacific is estimated to grow at a significant growth rate over the next few years.
 

• China's growth is driven due to its sizable aging demographic and increase in glaucoma-related vision impairments.
   
• The country’s rapidly growing elderly population leads to a greater burden of chronic eye diseases, including primary open-angle glaucoma. For instance, a population-based study showcased in Glaucoma Today estimated that one in 40 adults over 40 years of age suffers from glaucoma with visual impairment in China. This would imply roughly 60 million people globally could have had glaucoma in 2010, and one-third of these patients residing in China.
   
• By 2020, China’s population over 40 years is projected to reach 700 million, implying growing glaucoma patients to 24 million by 2020. These statistical findings represented that the aging population with glaucoma is expecting to spur the demand for effective treatment.
   
• In addition, enhanced healthcare facilities and increased availability of ophthalmic services subsequently improved the rates of diagnosis and treatment.
   
• Public health campaigns coupled with the adoption of sophisticated diagnostic instruments aid in raising health awareness, which promotes early detection and continuous treatment.
   
• Also, the presence of local and international pharmaceutical companies ensures there is adequate supply and competitive pricing for these drugs.
   
• Thus, the aforementioned factors allow China to leverage glaucoma treatment innovation and expansion in the Asia Pacific region, making them a key market contributor.
   

Saudi Arabia is anticipated to grow in the Middle East and Africa glaucoma treatment industry.
 

• The increasing awareness of eye care, along with the expanding elderly demographic, is expected to drive Saudi Arabia's growth substantially.
   
• In addition, early intervention programs and enhanced overall governmental attention to the country’s healthcare delivery system also improve glaucoma care and management services in the country.
   
• Furthermore, the growth of the market in this region will be further propelled by the development of those medical technologies and treatments.
   

Glaucoma Treatment Market Share

The top five players in the market accounted for nearly 45-55% of the market share. The major key players in the market include AbbVie, Novartis AG, Pfizer, Bausch + Lomb, and Aerie Pharmaceuticals established portfolios of intraocular pressure-lowering medications, including prostaglandin analogs and combination therapies. In addition, other emerging companies and biological corporations are focusing on development of novel drug classes, including Rho kinase inhibitors and sustained-release delivery systems, to diversify the market further.
 

Glaucoma Treatment Market Companies

Few of the prominent players operating in the glaucoma treatment industry include:

• AbbVie
• Alcon
• Bausch & Lomb
• Cipla
• Eyepoint Pharmaceuticals
• Grevis Pharmaceuticals
• Inotek Pharmaceuticals
• Merck
• Novartis
• Pfizer
• Santen Pharmaceutical
• Sun Pharmaceutical
• Teva Pharmaceutical
• Thea
   

AbbVie through Allergan, promotes a strong portfolio of glaucoma medications including Alphagan and Lumigan. It holds a leading position in the eye health industry bolstered by strong R&D pipelines and innovation in combination therapies and sustained release implants.
 

Novartis offers advanced services in ophthalmology with treatments such as Travatan Z. Its precision focus on medicine, clinical trial landscape, and investment in gene and cell therapies for eye diseases boosts its competitive advantage in providing advanced glaucoma innovations.
 

Bausch + Lomb provides a comprehensive range of ophthalmic products with a growing focus on solutions that are centric to the patient’s needs. The company’s glaucoma medications, especially Timoptic and Vyzulta, are buoyed by a dedication to cost and accessibility, complemented by robust market shares in both branded and surgical eyecare.
 

Glaucoma Treatment Industry News

• In April 2025, Akums Drugs & Pharmaceuticals unveiled a new combination therapy for glaucoma treatment. The combination of Ripasudil and Timolol in combination was developed to control eye pressure which is one of the most frequent reasons for glaucoma. This is the first combination treatment been approved in India by DCGI (Drug Controller General of India) for glaucoma treatment. The new treatment aimed to improve the outcomes of patients suffering from glaucoma in the Indian market.
   
• In November 2024, Glenmark Pharmaceuticals introduced a generic ophthalmic solution for the treatment of glaucoma. This Travoprost, is verified as bioequivalent and therapeutically equivalent to the reference-listed drug, Travatan Z ophthalmic solution. This introduction aimed to improve the availability of cost-effective medications while increasing patient access to effective glaucoma treatments.
   
• In November 2024, Santen Pharmaceutical Korea expanded the availability Rhopressa, a Rho-kinase inhibiting drug in South Korea. Rhopressa is used in the treatment of enhancing intraocular pressure amongst patients suffering from open angle glaucoma and ocular hypertension. This new product launch is likely to increase market expansion by further improving the treatment alternatives and access to modern treatment in the region.
   

The glaucoma treatment market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Disease Type

• Open angle glaucoma
• Angle closure glaucoma
• Other disease types

Market, By Drug Class

• Prostaglandin analogs
• Beta-blockers
• Alpha adrenergic agonist
• Carbonic anhydrase inhibitors
• Other drug classes

Market, By Formulation

• Solid
• Liquid

Market, By Age Group

• Below 18
• 19 - 40
• 41 - 60
• Above 60

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE